# Pulmonology Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Leonard Nimoy (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML017-SYN-TD
- Date: 2014-02-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Carla Benedetti, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- To: Owen Rasmussen, MD, Pulmonology
- Urgency: Routine, within four weeks

## Referral question

COPD in an 82-year-old former smoker, now confirmed on spirometry as GOLD 3. Please confirm the grade and group, review the inhaler choice and the place of an inhaled corticosteroid, assess his oxygen needs, and advise on pulmonary rehabilitation and lung cancer screening. **S**

## Questions for the consultant

1. Do you agree with GOLD 3, group B, and is anything other than COPD contributing to his breathlessness?
2. Is a long-acting bronchodilator pair in a soft mist inhaler the right start, and is there any place for an inhaled corticosteroid?
3. Does he need oxygen at rest or on exertion?
4. Does the alpha-1 antitrypsin level need further testing, and does he need chest CT for emphysema, lung volume reduction, or lung cancer screening?
5. Should he start pulmonary rehabilitation now, and what should we watch for?

## Pertinent history

COPD diagnosed by his previous clinician without spirometry on file; he describes breathlessness that stops him after about 100 meters (mMRC 3) and uses a wheelchair at airports. CAT 22. No exacerbation, antibiotic or prednisone course, or hospital stay in the past 12 months. Smoked heavily for about 25 years (about 40 pack-years) and quit about 30 years ago; no occupational exposure. Spirometry today: post-bronchodilator FEV1 1.26 L (46 percent predicted), FVC 2.93 L, FEV1/FVC 0.43. Blood eosinophils 0.18 x10³/µL; alpha-1 antitrypsin 138 mg/dL; hemoglobin 14.6 g/dL. Resting saturation 93 percent. ECG in sinus rhythm. PHQ-9 3. Started tiotropium-olodaterol soft mist inhaler today, with albuterol as needed. **S**

- Leonard Nimoy was born in Boston on March 26, 1931. **D**
- He played Mr. Spock in the Star Trek television series from 1966 to 1969, later acted in and directed Star Trek films, and directed other films, including the comedy Three Men and a Baby. **D**
- In a Twitter post at the end of January 2014 he announced that he had chronic obstructive pulmonary disease: "I quit smoking 30 yrs ago. Not soon enough. I have COPD. Grandpa says, quit now!! LLAP". **D**
- In early February 2014 he posted "I'm doing OK. Just can't walk distances," and ABC News reported that he had been seen at an airport in a wheelchair. **D**
- In February 2014 he urged smokers to quit: "Smokers, please understand. If you quit after you're diagnosed with lung damage it's too late." **D**

3 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: FEV1 before bronchodilator: 1.18 L (low); FEV1 after bronchodilator: 1.26 L (low); FEV1 percent predicted after bronchodilator: 46% (low); FVC after bronchodilator: 2.93 L; FEV1/FVC after bronchodilator: 0.43 (low); Blood eosinophil count: 0.18 10*3/uL; Alpha-1 antitrypsin: 138 mg/dL; Hemoglobin: 14.6 g/dL; Creatinine: 0.98 mg/dL; PHQ-9: 3. All results are synthetic.

BP 132/78 mmHg; pulse 84 bpm; respirations 20/min; temperature 36.7 °C; oxygen saturation 93% on room air; weight 80 kg; BMI 23.4 kg/m². All vital signs are synthetic.

## Current medications

- Albuterol 90 mcg/actuation inhaler, two inhalations as needed for breathlessness (prescribed by his previous clinician; used once or twice most days before intake) **S**
- Tiotropium-olodaterol 2.5/2.5 mcg soft mist inhaler, two inhalations once daily **S**

## Plan so far

- Start tiotropium-olodaterol 2.5/2.5 mcg soft mist inhaler, two inhalations each morning, keep albuterol as needed, and teach and check inhaler technique at every visit; no inhaled corticosteroid while there are no exacerbations and blood eosinophils are below 300 per microliter. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026) **S**
- At every visit: CAT, mMRC, exacerbations in the past 12 months, GOLD group, pulse oximetry, smoking status, BMI, and inhaler technique. Spirometry at diagnosis and at least yearly; alpha-1 antitrypsin once; blood eosinophils at baseline and before any change in inhaled corticosteroid; arterial blood gas only if resting saturation is 92 percent or less; long-term oxygen only for resting saturation of 88 percent or less confirmed twice at least three weeks apart; ECG and cardiovascular risk at baseline. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026); Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020) **S**
- Written COPD action plan: what an exacerbation looks like (more breathlessness, more or discolored sputum), when to use extra albuterol, and when to call the clinic the same day or go to emergency care. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026) **S**
- Lung cancer screening reviewed and not offered: he quit smoking more than 15 years ago, so he does not meet the USPSTF criteria despite more than 20 pack-years. Guideline: CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026); Lung Cancer: Screening (2021) **S**
- Vaccines for COPD: yearly influenza (high dose at 65 and older), PCV20 once, RSV once at 75 and older, COVID-19 by CDC guidance, Tdap every ten years, and recombinant zoster. Guideline: CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026); Adult Immunization Schedule by Age (2026) **S**
- Comorbidity and mood screening at intake and yearly (depression, anxiety, cardiovascular disease, osteoporosis, reflux, sleep, nutrition), and advance care planning at the wellness visit. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026) **S**
